Regeneron Pharmaceuticals Inc. buy Wells Fargo & Company
Summary
This prediction ended on 24.09.25 with a price of €480.00. The BUY prediction by Wells_Fargo___Compan for Regeneron Pharmaceuticals Inc. performed very badly with a performance of -51.79%. Dividends of €2.60 are taken into consideration when calculating the performance. Wells_Fargo___Compan has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -0.340% | -0.340% | 22.275% |
| iShares Core DAX® | 2.992% | 3.220% | 4.271% |
| iShares Nasdaq 100 | -1.584% | -3.172% | 24.749% |
| iShares Nikkei 225® | -2.254% | -9.924% | 43.518% |
| iShares S&P 500 | -0.009% | 1.641% | 20.967% |
Comments by Wells_Fargo___Compan for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
In the thread Trading Regeneron Pharmaceuticals Inc.
Stopped prediction by Wells_Fargo___Compan for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
30.04.25
30.04.26
01.05.26
Regeneron Pharmaceuticals Inc.
10.01.25
10.01.26
11.01.26
Regeneron Pharmaceuticals Inc.
02.08.24
02.08.25
03.08.25

